Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVET: Tacrolimus Induction with Vedolizumab in Ulcerative Colitis
NCT02954159Phase 3Terminated
- Sponsor
- Medical College of Wisconsin
- Start
- May 2017
- Primary completion
- Jan 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ulcerative colitis (UC) comparing Tacrolimus + Vedolizumab with Placebo + Vedolizumab (2 arms). Primary endpoint: Clinical Response at 6 weeks. Started May 2017; status: terminated.
02
Drugs
tacrolimus + Wuzhi capsule
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT02954159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02954159.